About TLC – Taiwan Liposome Company
TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage, specialty pharmaceutical company dedicated to the research and development of novel nanomedicines in pain management that maximize the potential of its proprietary lipid-assembled drug delivery platforms (LipAD®), which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing. Lead programs include TLC599 for osteoarthritis (OA) pain and TLC590 for postsurgical pain, which can potentially provide pain relief that lasts twice as long as current standards of care with a single administration, along with reduced toxicities.
TLC599 is a non-opioid, proprietary BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP). In a Phase II trial, a single intraarticular injection of TLC599 resulted in statistically significant and clinically meaningful improvement in pain relief in both WOMAC and VAS scores compared to placebo from Day 3 all the way through the end of the study at 24 weeks. Preclinical and MRI studies show TLC599 to have minimal cartilage damage and toxicity, and TLC599’s injection needle gauge flexibility grants potential expanded indications into small joints. A Phase III pivotal study evaluating the efficacy and safety of a single and repeated doses of TLC599 in patients with knee OA is ongoing.
TLC590 is a non-opioid, proprietary BioSeizer® sustained release formulation of ropivacaine whose application process is the same as current standard of care, with reduced cardiac and CNS local anesthetic system toxicity driven by its optimal formulation and selection of API. TLC590 has shown up to 7 days of postsurgical pain relief in a Phase I/II clinical trial in hernia repair surgery as well as in a Phase II clinical trial in bunionectomy.